{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T16:28:25Z","timestamp":1768667305821,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtct.2025.09.037","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:42:28Z","timestamp":1758710548000},"page":"61.e1-61.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Risk Factors on Long-Term Survival and Post-Transplant Failure Management in 200 Aggressive Non-Hodgkin Lymphoma Patients Who Underwent High-Dose Chemotherapy and Autologous Stem Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-0944","authenticated-orcid":false,"given":"Saad","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shahzad","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tusneem Ahmed M.","family":"Elhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-5817","authenticated-orcid":false,"given":"Irfan","family":"Maghfoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2025.09.037_bib0001","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.037_bib0002","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/ajh.27075","article-title":"2024 update: advances in the risk stratification and management of large B-cell lymphoma","volume":"98","author":"Tavakkoli","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.037_bib0003","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jtct.2025.09.037_bib0004","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.037_bib0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.037_bib0006","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jtct.2025.09.037_bib0007","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.037_bib0008","doi-asserted-by":"crossref","first-page":"55.e1","DOI":"10.1016\/j.bbmt.2020.09.004","article-title":"Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy","volume":"27","author":"Bal","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.037_bib0009","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.037_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2025.09.037_bib0011","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.037_bib0012","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.037_bib0013","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-024-01084-w","article-title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","volume":"14","author":"Shadman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.037_bib0014","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/10428190701843213","article-title":"Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients","volume":"49","author":"Akhtar","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.037_bib0015","doi-asserted-by":"crossref","first-page":"451.e1","DOI":"10.1016\/j.jtct.2023.04.002","article-title":"Impact of risk factors and long term survival analysis of patients with primary refractory Hodgkin lymphoma who underwent high dose chemotherapy and autologous stem cell transplant","volume":"29","author":"Akhtar","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.037_bib0016","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-016-2736-5","article-title":"Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma","volume":"95","author":"Akhtar","year":"2016","journal-title":"Ann Hematol"},{"issue":"27","key":"10.1016\/j.jtct.2025.09.037_bib0017","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.037_bib0018","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","article-title":"Regression modeling of competing risk using R: an in depth guide for clinicians","volume":"45","author":"Scrucca","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.037_bib0019","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2025.09.037_bib0020","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2024.42.16_suppl.7013","volume":"42","author":"Kamdar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.037_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.46989\/001c.115919","article-title":"Outcomes of Autologous stem cell transplantation in patients with primary refractory diffuse large B-cell lymphoma who demonstrate chemosensitivity to salvage chemotherapy","volume":"6","author":"Rauf","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.037_bib0022","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.037_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","volume":"55","author":"Gonz\u00e1lez-Barca","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.037_bib0024","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.037_bib0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:12:24Z","timestamp":1768630344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666636725014642"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.037","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Risk Factors on Long-Term Survival and Post-Transplant Failure Management in 200 Aggressive Non-Hodgkin Lymphoma Patients Who Underwent High-Dose Chemotherapy and Autologous Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}